UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
cSCC is one of the most common cancers in the U.S. and globally
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
